

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-Granzyme B antibody [EPR20129-217]

RRID:AB_2924920

Type: Antibody

Proper Citation

Abcam Cat# ab208586, RRID:AB_2924920

Antibody Information

URL: http://antibodyregistry.org/AB_2924920

Proper Citation: Abcam Cat# ab208586, RRID:AB_2924920

Target Antigen: Granzyme B

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, mIHC

Antibody Name: Recombinant Anti-Granzyme B antibody [EPR20129-217]

Description: This recombinant monoclonal targets Granzyme B

Target Organism: human

Clone ID: EPR20129-217

Antibody ID: AB_2924920

Vendor: Abcam

Catalog Number: ab208586

Record Creation Time: 20231110T031317+0000

Record Last Update: 20260830T034835+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Granzyme B antibody [EPR20129-217].

No alerts have been found for Recombinant Anti-Granzyme B antibody [EPR20129-217].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou X, et al. (2026) Single-cell profiling unveils an exhaustion trajectory of ZNF683hi tissue-resident alveolar CD8+ T cells in checkpoint inhibitor pneumonitis. Med (New York, N.Y.), 7(7), 101180.

Lopez-Lago MA, et al. (2026) Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med (New York, N.Y.), 7(7), 101149.

Cakmak P, et al. (2025) Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures. Immunity, 58(11), 2847.

Luo B, et al. (2025) Resveratrol amplifies the anti-tumor effect of ?-PD-1 by altering the intestinal microbiome and PGD2 content. Gut microbes, 17(1), 2447821.

Felices M, et al. (2023) Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. Cancer immunology research, 11(5), 674.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-? axis. Cell reports, 42(8), 112944.